DAL enters August with the most interesting tension sitting between a uniformly bullish analyst community and a stock that has given back ground since reporting earnings in mid-July.
The Street's post-earnings reaction was notable for its breadth. Every major firm that updated targets went higher — Morgan Stanley lifted to $125, JP Morgan jumped from $85 to $114, UBS moved to $112, TD Cowen to $112, and Citigroup to $110. All maintained positive ratings. Raymond James was the single outlier, stepping down from Strong Buy to Outperform while still raising its target from $80 to $104. The mean target of ~$105 implies roughly 20% upside to the current price of $87.44, and EPS momentum is running near the top of the universe — ranking in the 92nd percentile on 30-day momentum and 88th on 90-day. The valuation picture is less heroic: P/E has compressed about 2.5 points over the past 30 days to 11.2x, while EV/EBITDA at 7.1x has also eased. The factor scores paint a company with strong earnings momentum but a modest short score rank of 38 and a below-average analyst recommendation differentiation score of 6 — suggesting consensus is broadly positive but not sharply differentiated.
Short interest tells a quieter story than the price action might imply. Bears have been reducing exposure. SI fell roughly 11% on the week to 3.9% of the free float — not a particularly crowded short to begin with, and now moving in the wrong direction for anyone leaning against the stock. The borrow market reflects that ease: availability is extremely loose at over 1,000% of outstanding short interest, meaning shares to borrow are plentiful relative to demand. Cost to borrow is negligible at around 0.45%, barely changed on the week. There is no squeeze dynamic here and no sign of forced covering — the short reduction looks orderly.
Options positioning is mildly defensive but not alarming. The put/call ratio is running at 1.12, slightly above its 20-day average of 1.10 but only half a standard deviation above normal. This is well within the range of a stock where institutional holders routinely carry protective puts — it doesn't signal elevated fear. The 52-week range for the PCR runs from 0.63 to 1.23, so the current reading is comfortably in the upper-middle of that band.
The ownership picture adds context. Berkshire Hathaway holds roughly 6.1% of shares, sitting alongside BlackRock at 6.7% and Vanguard entities together approaching 10%. That anchor ownership base has historically damped downside volatility. On the insider side, the recent flow has been one-directional: sells by the COO, a division president, and the HR director between April and June, with CEO Ed Bastian selling 100,000 shares in February at $70.26. None of these trades read as panic — most appear scheduled — but there has been no offsetting buying, and the 90-day net represents roughly $11.3m in outflows at the executive level.
The stock is down 6.6% over the past month despite the earnings-driven analyst upgrades, recovering about 2.8% this week from the post-results low. The July 10 earnings print produced a 3.2% single-day drop and a 5.4% five-day decline — the market initially punished the report despite guidance that prompted widespread target raises. That gap between Street enthusiasm and price reaction is the central tension worth watching as the market works through whether DAL's premium expansion story justifies the re-rating analysts are assigning ahead of next quarter's data.
See the live data behind this article on ORTEX.
Open DAL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
